HC Wainwright restated their buy rating on shares of Interpace Diagnostics Group (NASDAQ:IDXG) in a research note issued to investors on Friday morning, BenzingaRatingsTable reports. The firm currently has a $11.00 price target on the business services provider’s stock, down from their previous price target of $12.00.
Several other research firms have also recently issued reports on IDXG. Janney Montgomery Scott began coverage on Interpace Diagnostics Group in a report on Wednesday, April 15th. They issued a buy rating on the stock. ValuEngine upgraded Interpace Diagnostics Group from a buy rating to a strong-buy rating in a report on Wednesday, June 17th. Alliance Global Partners reduced their target price on Interpace Diagnostics Group from $21.00 to $9.25 and set a buy rating on the stock in a report on Thursday, April 23rd. Finally, Maxim Group restated a buy rating and set a $12.00 target price on shares of Interpace Diagnostics Group in a report on Friday, April 24th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $8.81.
Interpace Diagnostics Group stock opened at $4.73 on Friday. The business’s 50-day simple moving average is $5.10 and its 200 day simple moving average is $5.22. The stock has a market cap of $19.19 million, a price-to-earnings ratio of -0.56 and a beta of 1.66. Interpace Diagnostics Group has a 12-month low of $3.81 and a 12-month high of $11.00. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.43.
Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings results on Thursday, June 25th. The business services provider reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($1.08). The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $8.95 million. Interpace Diagnostics Group had a negative net margin of 110.80% and a negative return on equity of 119.88%. As a group, sell-side analysts expect that Interpace Diagnostics Group will post -4.11 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDXG. Essex Investment Management Co. LLC raised its position in shares of Interpace Diagnostics Group by 3.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 669,427 shares of the business services provider’s stock worth $335,000 after purchasing an additional 23,658 shares during the period. UBS Group AG acquired a new stake in shares of Interpace Diagnostics Group during the fourth quarter worth about $91,000. Finally, Cambridge Investment Research Advisors Inc. raised its position in shares of Interpace Diagnostics Group by 16.6% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 54,900 shares of the business services provider’s stock worth $27,000 after purchasing an additional 7,800 shares during the period. 20.97% of the stock is currently owned by institutional investors.
About Interpace Diagnostics Group
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Featured Article: Economic Bubble
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.